Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon Pivotal Post-Approval Study

NCT03421561 is registered in ClinicalTrials.gov with Spectranetics Corporation as lead sponsor.

NCT NCT03421561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03421561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon Pivotal Post-Approval Study
Lead sponsor
Spectranetics Corporation
Phase
Not applicable
Overall status
Completed
Start date
June 18, 2013
Completion date
October 6, 2020
Enrollment
300 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral artery disease